Table 3 Perioperative Characteristics of the Subgroups Classified with Baseline eGFR
15 ≤ eGFR < 30 ml/min/1.73m2 | 30 ≤ eGFR < 45 ml/min/1.73m2 | 45 ≤ eGFR < 60 ml/min/1.73m2 | |||||||
|---|---|---|---|---|---|---|---|---|---|
Characteristics | Non-AKI (N = 25) | Postoperative AKI (N = 23) | p | Non-AKI (N = 81) | Postoperative AKI (N = 103) | p | Non-AKI (N = 353) | Postoperative AKI (N = 303) | p |
Demographic data | |||||||||
Male (%) | 12 (48) | 8 (34.8) | 0.394 | 36 (44.4) | 77 (74.8) | < 0.001 | 193 (54.8) | 180 (59.4) | 0.269 |
Age (years) | 67.68 ± 5.88 | 65.43 ± 8.77 | 0.398 | 66.63 ± 8.71 | 66.50 ± 7.56 | 0.914 | 65.83 ± 7.89 | 66.6 ± 7.58 | 0.209 |
BMI (kg/m2) | 22.99 ± 2.61 | 22.97 ± 2.91 | 0.981 | 23.29 ± 3.00 | 23.19 ± 3.10 | 0.825 | 23.48 ± 2.97 | 23.60 ± 3.06 | 0.62 |
Comorbidities | |||||||||
Hypertension (%) | 16 (64) | 19 (82.6) | 0.200 | 47 (58.0) | 59 (57.3) | 0.882 | 177 (50.4) | 178 (58.7) | 0.034 |
DM (%) | 7 (28) | 11 (47.8) | 0.234 | 22 (27.2) | 23 (22.3) | 0.491 | 52 (14.8) | 51 (16.8) | 0.519 |
NYHA grade 3–4 (%) | 15 (68.2) | 17 (77.3) | 0.736 | 54 (70.1) | 72 (73.5) | 0.735 | 219 (67.2) | 193 (66.6) | 0.913 |
LVEF | 54 ± 9 | 53 ± 11 | 0.812 | 59 ± 10 | 56 ± 12 | 0.151 | 58 ± 59 | 57 ± 9 | 0.152 |
Interval between angiography and surgery (days) | 7 (3,17) | 3 (1,6) | 0.014 | 6 (3,12) | 5 (2,7) | 0.015 | 4 (2,6) | 4 (2,6) | 0.786 |
0-2d | 7 (28.0) | 13 (56.5) | 0.078 | 25 (30.9) | 41 (39.8) | 0.220 | 155 (43.9) | 142 (46.9) | 0.479 |
3-6d | 4 (16.0) | 7 (30.4) | 0.311 | 22 (27.2) | 38 (36.9) | 0.205 | 110 (31.3) | 99 (32.7) | 0.737 |
≥7d | 14 (56) | 3 (13.0) | 0.003 | 34 (42.0) | 24 (23.3) | 0.01 | 88 (25.0) | 62 (20.5) | 0.192 |
Contrast volume (ml) | 70 (50,90) | 65 (50,100) | 0.943 | 70 (60,90) | 70 (60,90) | 0.914 | 70 (60,90) | 70 (60,90) | 0.449 |
Contrast volume/ eGFR ratio | 5.09 ± 4.81 | 3.42 ± 1.88 | 0.126 | 2.04 ± 0.95 | 1.97 ± 0.707 | 0.601 | 1.41 ± 0.425 | 1.41 ± 0.435 | 0.894 |
Baseline laboratory indices | |||||||||
Hemoglobin (g/L) | 114.56 ± 14.65 | 107.41 ± 19.24 | 0.156 | 130.08 ± 14.91 | 126.93 ± 18.08 | 0.216 | 131.17 ± 15.87 | 127.07 ± 17.31 | 0.002 |
Albumin (g/L) | 39.0 ± 3.28 | 37.79 ± 6.09 | 0.406 | 39.97 ± 3.99 | 39.30 ± 3.49 | 0.254 | 40.32 ± 3.55 | 39.4 ± 3.54 | 0.002 |
BUN (mmol/L) | 14.55 ± 4.65 | 19.69 ± 10.06 | 0.035 | 11.78 ± 4.84 | 11.54 ± 4.25 | 0.729 | 8.33 ± 2.68 | 8.38 ± 2.80 | 0.807 |
Serum creatinine (µmol/L) | 228.23 ± 66.76 | 312.48 ± 182.23 | 0.042 | 145.19 ± 22.454 | 154.41 ± 22.92 | 0.007 | 111.58 ± 16.39 | 114.14 ± 16.86 | 0.05 |
Uric acid(µmol/L) | 519.25 ± 136.65 | 722.26 ± 514.89 | 0.113 | 502.67 ± 139.46 | 545.94 ± 122.76 | 0.04 | 443.19 ± 123.97 | 464.99 ± 171.19 | 0.073 |
Surgery | |||||||||
Sole Valve (%) | 15 (60) | 14 (60.9) | 0.752 | 42 (51.9) | 53 (51.5) | 0.898 | 218 (61.9) | 174 (57.4) | 0.132 |
Sole CABG (%) | 9 (36) | 8 (34.7) | 0.662 | 36 (44.4) | 38 (36.9) | 0.152 | 118 (33.6) | 94(31.0) | 0.685 |
Valve & CABG (%) | 1 (4.0) | 1 (4.3) | 0.886 | 3 (3.7) | 12 (11.7) | 0.069 | 16 (4.5) | 35 (11.5) | 0.003 |
CPB duration (mins) | 110 (82,121) | 97 (82,119) | 0.611 | 105 (84,136) | 101 (76,132) | 0.574 | 85 (68,112) | 105(77,129) | < 0.001 |
Cross-clamp duration (mins) | 65.94 ± 27.48 | 59 ± 20.9 | 0.482 | 61.90 ± 27.01 | 61.61 ± 29.65 | 0.960 | 55.86 ± 24.34 | 62.27 ± 26.67 | 0.011 |
Prognosis | |||||||||
In-hospital mortality | 1 (4) | 2 (8.7) | 0.601 | 0 (0) | 6(5.8) | 0.019 | 2 (0.6) | 8 (2.6) | 0.031 |
Length of hospital stay (days) | 19 (13,33) | 18 (12,24) | 0.347 | 15 (11,22) | 15 (12,21) | 0.652 | 13 (11,17) | 15 (12,20) | 0.003 |